Literature DB >> 20616582

Molecular signature of early hepatocellular carcinoma.

Arief Suriawinata1, Swan N Thung.   

Abstract

The advances in imaging techniques and establishment of screening and surveillance protocols for high-risk populations for hepatocellular carcinoma (HCC) have led to the detection of small hepatic nodules in patients with chronic liver diseases, but in general the prognosis for HCC remains poor. Early detection of HCC or detection of small/early HCC followed by appropriate treatment is the key to significantly alter the prognosis and significantly decrease tumor-related deaths. Recent advances in gene profiling have led to a better understanding in early hepatocarcinogenesis and have suggested several possible molecular signatures which are able to separate early HCCs from their precursors, the dysplastic nodules. The continued search for new and more accurate molecular signatures must be translated into the clinical setting, where they can advance screening and surveillance of high-risk patients in the detection of early HCC. Copyright (c) 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20616582     DOI: 10.1159/000315228

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  3 in total

1.  Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria?

Authors:  Matthew P Landman; Irene D Feurer; C Wright Pinson; Derek E Moore
Journal:  HPB (Oxford)       Date:  2011-08-19       Impact factor: 3.647

2.  Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.

Authors:  Taiseer R Ibrahim; Samar M Abdel-Raouf
Journal:  Pathol Oncol Res       Date:  2014-08-10       Impact factor: 3.201

3.  TP53 R72P polymorphism modulates DNA methylation in hepatocellular carcinoma.

Authors:  Khadija Rebbani; Agnès Marchio; Sayeh Ezzikouri; Rajaa Afifi; Mostafa Kandil; Olfa Bahri; Henda Triki; Abdellah Essaid El Feydi; Anne Dejean; Soumaya Benjelloun; Pascal Pineau
Journal:  Mol Cancer       Date:  2015-04-02       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.